相关实验视频
Updated: Jun 5, 2025

Anti-Nuclear Antibody Screening Using HEp-2 Cells
Published on: June 23, 2014
反维生素D抗体的抗体
Jozélio Freire de Carvalho1, Thelma L Skare2, Ana Tereza Amoedo Martinez3
1Núcleo de Pesquisa em Doenças Crônicas não Transmissíveis (NUPEC), School of Nutrition from the Federal University of Bahia, Salvador, Bahia, Brazil.
抗维生素D抗体在患有自身免疫性疾病的患者中发现,如狼和硬化皮质. 它们的存在可能在疾病的发展和进展中发挥作用,与其他自身抗体结合.
科学领域:
- 免疫学 免疫学 免疫学
- 内分泌学 在内分泌学.
- 类风湿病学 类风湿病学
背景情况:
- 低维生素D水平在自身免疫性疾病中很常见.
- 抗维生素D抗体可能导致维生素D缺乏,并影响自身免疫过程.
研究的目的:
- 审查对自身免疫性疾病中抗维生素D抗体的研究.
- 分析这些抗体的患病率和相关性.
主要方法:
- 三项研究的系统审查.
- 分析了345名患有全身性红斑狼 (SLE),硬质皮质炎 (SSc),初级抗脂抗体综合征 (pAPS) 和黄 (PV) 的患者的数据.
主要成果:
- 维生素D缺乏是普遍存在的 (57.1%-82.1%).
- 抗维生素D抗体在pAPS的3.5%到SSc的87%不等.
- 与SLE (抗dsDNA) 和SSc (疾病本身) 中的疾病标志物相关的抗体.
结论:
- 抗维生素D抗体存在于许多患有各种自身免疫性疾病的患者中.
- 这些抗体可能参与自身免疫性疾病的机制和进展.
更多相关视频
10:46A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
Published on: December 9, 2015
10:05Simultaneous Distinction of Monospecific and Mixed DFS70 Patterns During ANA Screening with a Novel HEp-2 ELITE/DFS70 Knockout Substrate
Published on: January 17, 2018
相关概念视频
Role of Skin in Vitamin D Synthesis
The solar UV B rays (290-315 nm) are absorbed by the skin, and 7-dehydrocholesterol (provitamin D3) photolyzes it to previtamin D3, which undergoes a rapid transformation to vitamin...
Blood Transfusion and Agglutination
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
Blood Typing
Antigens are protein molecules that reside on the surface of red blood cells (RBCs). The ABO and Rh blood typing systems target...
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
Humoral Immune Responses